Search
MaxCyte Inc
MXCTAdd to Watchlist
1.195USD
+0.015+1.27%
Close 09-17 16:00（ET）
126.83MMarket Cap
LossP/E TTM
MaxCyte Inc (MXCT) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to MaxCyte Inc in the past month.
Buy
3 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
4.107USD+245.17%
MXCT Analyst Recommendation Trends
In the current month, MXCT has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MXCT average Analyst price target in the last month is 4.108.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
7
7
7
7
7
7
MXCT Analyst Rating for Peer Comparison
Updated: Sep 17, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Intuitive Surgical Inc
ISRG
11
13
9
1
0
34
Boston Scientific Corp
BSX
11
17
6
0
0
34
Edwards Lifesciences Corp
EW
10
14
8
0
0
32
Thermo Fisher Scientific Inc
TMO
10
16
6
0
0
32
Veeva Systems Inc
VEEV
7
15
8
1
0
31
Danaher Corp
DHR
11
13
4
0
0
28
Waters Corp
WAT
8
10
9
0
0
27
Agilent Technologies Inc
A
6
11
7
0
0
24
Illumina Inc
ILMN
5
7
7
2
1
22
Resmed Inc
RMD
2
7
10
1
1
21
Financial Forecasting
Based on analysts' estimates, MXCT EPS is projected to reach -0.083 in FY2026Q3, following reported EPS of -0.083 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.08
-0.08
-0.09
-0.08
-0.07
Actual
-0.09
-0.04
-0.08
--
--
Surprise
-12.37%
+44.45%
+7.70%
--
--
FAQs
What is MaxCyte Inc's expected revenue for the next quarter?
MaxCyte Inc's expected revenue is 7.05M.
What is MaxCyte Inc's price target?
Analysts forecast that MaxCyte Inc's price target is USD 4.11, with the highest forecast at USD 5.00 and the lowest forecast at USD 2.43.
How have MaxCyte IncMXCT's recent earnings per share performed?
The market expectation was USD -0.08, while MaxCyte IncMXCT's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for MaxCyte Inc?
Based on the ratings of MaxCyte Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.